Coverage 1 publisher
Articles stay on their publishers’ sites; each link opens the original.
The scariest thing about gray-market peptides is how little we know
A commentary examines the lack of reliable information about gray-market peptides compared with drugs tested in formal clinical trials. It describes the difficulty of finding concrete data about these products.